The latest positive readout comes from the APPLY-PNH study, which pitted iptacopan against AstraZeneca/Alexion's anti-C5 antibodies Soliris (eculizumab) and Ultomiris (ravulizumab) in adults with ...

The Swiss pharma group said this morning that the top-line results of the APPOINT-PNH trial showed that iptacopan provided “clinically meaningful” increases in haemoglobin levels in patients ...

Health Canada has approved Novartis Canada’s Fabhalta (iptacopan capsules) as the first oral monotherapy to treat adults with paroxysmal ... healthcare system. The company invests more than ...